Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Combined onabotulinumtoxinA/atogepant treatment blocks activation/sensitization of high-threshold and wide-dynamic range neurons

Cephalalgia(2020)10.1177/0333102420970507Source: DataRank Database

Combined onabotulinumtoxinA/atogepant treatment blocks activation/sensitization of high-threshold and wide-dynamic range neurons is a research paper published in Cephalalgia (2020). On theSindex it has a DataRank of 0. It has been cited 47 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access47 citations

Download PDF

Cite:

Linked data & code

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (12 grants)Impact (FWCI 3.68)OA: hybridTopics (45)Linked Datasets (6)DataCite Reuse (6)IDs (PubMed, PMC, OpenAlex)SDGs (3)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (6)

Andrew M. Strassman ORCID,Aaron Schain ORCID,Aubrey Manack Adams,Mitchell F. Brin ORCID,Rami Burstein ORCID

Live enrichment

PubMed:33200944 PMC:PMC7786391 OpenAlex:https://openalex.org/W3103986674

National Institute of Neurological Disorders and Stroke

Grant: NS079678

National Institute of Neurological Disorders and Stroke

Grant: NS094198

National Institute of Neurological Disorders and Stroke

Grant: NS106345

NINDS NIH HHS

Grant: R21 NS106345

NINDS NIH HHS

Grant: R37 NS079678

NINDS NIH HHS

Grant: R01 NS069847

NINDS NIH HHS

Grant: R01 NS094198

National Institutes of Health

Grant: 1R21NS106345-01

Characterization of sleep behavior in a rodent model of headache

National Institutes of Health

Grant: 5R37NS079678-06

Photophobia during migraine: sensory, autonomic and emotional responses to light

Allergan

Grant: unidentified

unidentified

National Institutes of Health

Grant: 5R01NS094198-04

Cortical Mechanisms of Headache: Beyond CSD

Allergan

FWCI

3.68

Citation Percentile

0.9%

Citation Trend

2021

2022

2023

2024

2025

2026

hybridLicense: cc-by-nc

journalhttps://journals.sagepub.com/doi/pdf/10.1177/0333102420970507

publisherhttps://journals.sagepub.com/doi/pdf/10.1177/0333102420970507

publisherhttps://journals.sagepub.com/doi/full-xml/10.1177/0333102420970507

journalhttps://doi.org/10.1177/0333102420970507

repositoryhttps://pubmed.ncbi.nlm.nih.gov/33200944

Fields of Study

Migraine and Headache StudiesNeuroscience of respiration and sleepNicotinic Acetylcholine Receptors Study03 medical and health sciences0302 clinical medicine

MeSH Terms

AnalgesicsAnimalsCalcitoninHumansMigraine DisordersPiperidinesPyridinesPyrrolesSpiro CompoundsRats, Sprague-DawleyBotulinum Toxins, Type ANerve Fibers, UnmyelinatedRats

Keywords

MedicineSensitizationWide dynamic rangeNeuroscienceComputer scienceBiologyImmunologyCGRPMigraineHeadachecortical spreading depressionTrigeminalMeningeal NociceptorCalcitoninAnalgesicsNerve Fibers, UnmyelinatedPyridinesMigraine DisordersOriginal ArticlesRatsRats, Sprague-DawleyPiperidinesAnimalsHumansPyrrolesSpiro CompoundsBotulinum Toxins, Type A

Sustainable Development Goals

SDG 2: 2. Zero hungerSDG 3: 3. Good healthSDG 0: Good health and well-being

Additional file 1 of Real-world effectiveness, satisfaction, and optimization of ubrogepant for the acute treatment of migraine in combination with onabotulinumtoxinA: results from the COURAGE Study

10.6084/m9.figshare.23849622figshare

Additional file 1 of Real-world effectiveness, satisfaction, and optimization of ubrogepant for the acute treatment of migraine in combination with onabotulinumtoxinA: results from the COURAGE Study

10.6084/m9.figshare.23849622.v1figshare

Additional file 2 of Real-world effectiveness, satisfaction, and optimization of ubrogepant for the acute treatment of migraine in combination with onabotulinumtoxinA: results from the COURAGE Study

10.6084/m9.figshare.23849625.v1figshare

Additional file 2 of Real-world effectiveness, satisfaction, and optimization of ubrogepant for the acute treatment of migraine in combination with onabotulinumtoxinA: results from the COURAGE Study

10.6084/m9.figshare.23849625figshare

Additional file 3 of Real-world effectiveness, satisfaction, and optimization of ubrogepant for the acute treatment of migraine in combination with onabotulinumtoxinA: results from the COURAGE Study

10.6084/m9.figshare.23849628.v1figshare

Additional file 3 of Real-world effectiveness, satisfaction, and optimization of ubrogepant for the acute treatment of migraine in combination with onabotulinumtoxinA: results from the COURAGE Study

10.6084/m9.figshare.23849628figshare